Eoflow (294090) Q2 2025 earnings summary

Executive summary

• Specializes in wearable medical devices, notably insulin pumps, leveraging proprietary electro-osmotic pump technology for diabetes management.

• Expanded product portfolio includes EOPatch, EOPatch X (artificial pancreas), and EOPani (integrated sensor-pump system), with regulatory approvals in Korea, Europe, UAE, and Indonesia.

• Faced significant legal challenges, including a $59.4 million damages ruling and sales ban in the US and Europe due to intellectual property disputes with Insulet Corporation.

• Ongoing restructuring and liquidity management efforts amid continued operating losses and high leverage.

Financial highlights

• H1 2025 consolidated revenue: KRW 1.90 billion, down from KRW 3.13 billion in H1 2024.

• Operating loss for H1 2025: KRW 107.9 billion, significantly higher than KRW 27.3 billion loss in H1 2024.

• Net loss attributable to owners: KRW 116.1 billion for H1 2025, compared to KRW 20.9 billion in H1 2024.

• Basic loss per share: KRW 3,476 for H1 2025, versus KRW 687 in H1 2024.

• Cash and cash equivalents at June 30, 2025: KRW 2.38 billion, down from KRW 3.39 billion at year-end 2024.

Outlook and guidance

• Management is focused on improving liquidity, cost structure, and operational efficiency, while actively defending ongoing litigation and seeking new funding sources.

• Regulatory and legal uncertainties, especially regarding product sales in key markets, are expected to persist.